Wheeler Bio Partners with Mitsubishi Corporation for Growth
Wheeler Bio is taking a significant step in expanding its operations through a newly formed strategic partnership with Mitsubishi Corporation. This collaboration aims to enhance Wheeler's business development activities in the Asia-Pacific market.
Investment and Opportunities
Mitsubishi Corporation, recognizing the potential of Wheeler Bio, plans to invest in the company’s Series A-1 financing. By leveraging its extensive regional network and industry relationships, Mitsubishi intends to connect with biotech innovators across various Asia-Pacific nations.
Expanding Biotech Innovations
Under this partnership, Mitsubishi Corporation will focus on establishing strong ties with biotech innovators in several key markets, seeking to offer U.S. development and cGMP manufacturing capabilities. The cooperation aims to recruit new clients and link them with Wheeler's advanced ModularCMC™ platform for efficient biomanufacturing.
Enhancing Manufacturing Solutions
As the demand for U.S.-based biomanufacturing rises, the ModularCMC™ platform is uniquely positioned to expedite the process of moving from discovery to clinical development for antibody-based therapeutics. This platform emphasizes speed, agility, and scalability, ensuring a comprehensive approach to biological innovations.
Leadership Insights
Takahiro Tokuda, COO of Mitsubishi Corporation's Healthcare Division, expressed confidence in this partnership, stating that it would significantly accelerate the development of biopharmaceuticals in the Asia-Pacific region, ultimately enhancing people's lives through advanced healthcare solutions.
Wheeler Bio's Vision and Commitment
Patrick Lucy, President and CEO of Wheeler Bio, highlighted the importance of this partnership, stating that Mitsubishi's investment and guidance would bolster their business development efforts as they scale operations. The deep expertise of Mitsubishi in biologics contract manufacturing is seen as essential for achieving growth objectives.
About Wheeler Bio
Wheeler Bio operates as a pioneering contract development and manufacturing organization. Their ModularCMC™ platform stands out for enabling rapid progression from discovery to clinical phases for antibody therapeutics, while ensuring scalability to support further development and commercialization.
The Role of Mitsubishi Corporation
Mitsubishi Corporation is recognized as a leading trading and investment company that emphasizes addressing healthcare needs. Their Healthcare Division is dedicated to providing solutions in medical care, nursing, prevention, pharmaceuticals, and agrochemicals, striving to solve various customer challenges, particularly in the pharmaceutical domain.
Contact Information
If you're interested in learning more about Wheeler Bio or this partnership, you can reach out at:
Wheeler Bio, Inc.
Contact: jpolston@wheelerbio.com
Frequently Asked Questions
What is the main objective of the Wheeler Bio and Mitsubishi Corporation partnership?
The partnership aims to enhance Wheeler’s business development activities in the Asia-Pacific region and streamline access to U.S. biomanufacturing.
What does the ModularCMC™ platform offer?
The ModularCMC™ platform facilitates a rapid transition from discovery to clinical development for antibody-based therapeutics, ensuring scalability in the process.
How will Mitsubishi Corporation support Wheeler Bio?
Mitsubishi Corporation will leverage its extensive network and expertise to identify biotech innovators and facilitate connections to Wheeler Bio’s services.
What market regions are targeted in this partnership?
The partnership specifically targets biotech innovators across various countries within the Asia-Pacific region.
Who can be contacted for more information regarding Wheeler Bio?
For inquiries, individuals can reach out to Wheeler Bio via email at jpolston@wheelerbio.com.
